Abstract:Short major histocompatibility complex (MHC) class I (MHC-I)-restricted peptides contain the minimal biochemical information to induce antigen (Ag)-specific CD8+ cytotoxic T cell responses but are generally ineffective in doing so. To address this, we developed a cobalt–porphyrin (CoPoP) liposome vaccine adjuvant system that induces rapid particleization of conventional, short synthetic MHC-I epitopes, leading to strong cellular immune responses at nanogram dosing. Along with CoPoP (to induce particle formation of peptides), synthetic monophosphoryl lipid A (PHAD) and QS-21 immunostimulatory molecules were included in the liposome bilayer to generate the "CPQ" adjuvant system. In mice, immunization with a short MHC-I-restricted peptide, derived from glycoprotein 70 (gp70), admixed with CPQ safely generated functional, Ag-specific CD8+ T cells, resulting in the rejection of multiple tumor cell lines, with durable immunity. When cobalt was omitted, the otherwise identical peptide and adjuvant components did not result in peptide binding and were incapable of inducing immune responses, demonstrating the importance of stable particle formation. Immunization with the liposomal vaccine was well-tolerated and could control local and metastatic disease in a therapeutic setting. Mechanistic studies showed that particle-based peptides were better taken up by antigen-presenting cells, where they were putatively released within endosomes and phagosomes for display on MHC-I surfaces. On the basis of the potency of the approach, the platform was demonstrated as a tool for in vivo epitope screening of peptide microlibraries comprising a hundred peptides.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c07680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c07680</a>.Supporting methods; figures showing synthesis schemes, 1H and 13C NMR and mass spectra, HPLC traces, cryo-electron micrographs, peptide bindings to liposomes, gating results, CPQ/A5 vaccination effects, impacts of PHAD, QS-21 and antigens, optional solubility tag effects, QS-21 and antigen dosage effects, liposomes draining, vaccine injection effects at multiple sites, macrophage uptake, PoP lipids coated on silica beads, liposome/peptide complexes, A5 with 2 his-tag released, fluorescence integrity, various length impacts of A5, QS-21 and peptide dose effects, CPQ as platform, details of peptide binding, cytotoxicities, Rragc385 DNA sequencing, and antitumor efficacy; tables listing 1H shifts and assignments, ICP analysis, representative UV–vis absorptions, polydispersities and ζ potentials, A5 peptides, and properties of A5 related and synthetic peptides (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c07680/suppl_file/nn0c07680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Cancer/Testis Antigen HCA587-Derived Long Peptide Vaccine Generates Potent Immunologic Responses and Antitumor Effects in Mouse Model

HCA587/MAGE-C2 protein formulated with CFA and CpG elicits potent immune responses and antitumor effects in mice

Induction of HCA587-Specific Antitumor Immunity with HCA587 Protein Formulated with CpG and ISCOM in Mice

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4+ T-cells Expressing Granzyme B in a Mouse Model of Melanoma.

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Abstract 4106: A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model

Efficacy of MAGE-A4 Long Peptide As a Universal Immunoprevention Cancer Vaccine

Identification of Promiscuous HLA‐DR‐restricted CD4+ T‐cell Epitopes on the Cancer‐testis Antigen HCA587

Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice

Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects

Abstract 5345: Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines

Peptide Vaccination – a Novel Therapeutically Option for Cancer Patients

Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.

Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy

Peptide Mimics of A Carbohydrate-Associated Epitope Expressed by Cancer Cells: Identification of Vaccine Candidates

Vaccination with Immunoglobulin Frame Region-Derived Nonapeptide Elicits Cellular Immune Response Against Lymphoma in Human Leukocyte Antigen-A2.1 Transgenic Mice

Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.

Immunization with short peptide particles reveals a functional CD8 + T-cell neoepitope in a murine renal carcinoma model

A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8 + T Cell Epitopes